Absorption: Tequin is well absorbed from the gastrointestinal tract after oral administration and can be given without regard to food. The absolute bioavailability of Tequin is 96%. Peak plasma concentrations of Tequin usually occur 1-2 hours after oral dosing.

Distribution: Serum protein binding of Tequin is approximately 20%.

Metabolism: Tequin undergoes limited biotransformation in humans with less than 1% of the dose excreted in the urine.

Excretion: Tequin is excreted as unchanged drug primarily by the kidney.

Adverse Reactions

Abdominal pain, anorexia, constipation, dyspepsia, gastritis, glossitis, mouth ulcers, nausea, vomiting, and taste perversion. Tequin should be avoided in those patients with hypokalemia (low blood potassium). Diuretics such as furosemide and hydrochlorothiazide may cause hypokalemia. Disturbances of blood sugar, including symptoms of hyperglycemia (high blood sugar) and hypoglycemia (low blood sugar) have been reported in diabetic patients treated with Tequin and oral antidiabetic drugs, with or without insulin. Other people at particular risk for serious hyperglycemia include those who may have unrecognized diabetes, decreased renal function, underlying medical problems, or people more than 75 years of age.